Literature DB >> 759066

Bromocriptine inhibits norepinephrine release.

M G Ziegler, C R Lake, A C Williams, P F Teychenne, I Shoulson, O Steinsland.   

Abstract

Bromocriptine is a dopamine agonist that induces postural hypotension and can be used as an antihypertensive. The drug inhibits release of norepinephrine (NE) from an isolated artery by stimulating presynaptic receptors. In normotensive subjects it lowers both plasma and cerebrospinal fluid (CSF) levels of NE by 50% and lowers blood pressure moderately in standing subjects and slightly in recumbent subjects. Through central and peripheral mechanisms, bromocriptine inhibits sympathetic nervous discharge of NE.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 759066     DOI: 10.1002/cpt1979252137

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  12 in total

Review 1.  Diagnostic problems in pheochromocytoma.

Authors:  M Mannelli
Journal:  J Endocrinol Invest       Date:  1989-11       Impact factor: 4.256

2.  Increased forearm vascular resistance after dopamine blockade.

Authors:  D Mannering; E D Bennett; N Mehta; F Kemp
Journal:  Br J Clin Pharmacol       Date:  1984-04       Impact factor: 4.335

3.  Hemodynamic alterations produced by N,N-Di-n-propyldopamine in anesthetized dogs.

Authors:  R A Hahn; B R MacDonald
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-10       Impact factor: 3.000

4.  Influence of dopaminergic mechanisms on 24-hour secretory patterns of prolactin, luteinizing hormone and testosterone in recumbent men.

Authors:  J R Sowers; S P Viosca; C Windsor; S G Korenman
Journal:  J Endocrinol Invest       Date:  1983-02       Impact factor: 4.256

5.  Stimulation of sympathetic activity by carbon dioxide in patients with autonomic failure compared to normal subjects.

Authors:  S Braune; A Hetzel; A Prasse; K Dohms; B Guschlbauer; C H Lücking
Journal:  Clin Auton Res       Date:  1997-12       Impact factor: 4.435

6.  DL-3,4-threo-DOPS in Parkinson's disease: effects on orthostatic hypotension and dizziness.

Authors:  W Birkmayer; G Birkmayer; H Lechner; P Riederer
Journal:  J Neural Transm       Date:  1983       Impact factor: 3.575

7.  Effect of bromocriptine on plasma catecholamines in normal subjects and prolactin-secreting tumor patients.

Authors:  A M Mancini; M Barontini; I Armando; G Levin; A Kleiman; J Razumny; I Molocznik
Journal:  J Endocrinol Invest       Date:  1986-06       Impact factor: 4.256

8.  Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study.

Authors:  H Przuntek; D Welzel; M Gerlach; E Blümner; W Danielczyk; H J Kaiser; P H Kraus; H Letzel; P Riederer; K Uberla
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

9.  Does endogenous dopamine modulate human sympathetic activity through DA2 receptors?

Authors:  M Mannelli; M L De Feo; M Maggi; A Salvetti; G Giusti; M Serio
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

10.  The effect of bromocriptine on plasma catecholamine concentrations in normal volunteers.

Authors:  L Steardo; E Di Stasio; S Bonuso; M Maj
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.